No data available.
No data available.
| S.No. | Ticker | Company | Market Cap | P/E | P/S | Total Debt (Qtr) |
|---|---|---|---|---|---|---|
| 1 | SMMT | Summit Therapeutics Inc. | 1,233.43 Bn | -1,338.33 | 0.00 | 0.01 Bn |
| 2 | ONC | BeOne Medicines Ltd. | 458.30 Bn | 6,685.60 | 92.16 | 1.90 Bn |
| 3 | VRTX | Vertex Pharmaceuticals Inc / Ma | 113.54 Bn | 30.89 | 9.68 | 1.83 Bn |
| 4 | REGN | Regeneron Pharmaceuticals, Inc. | 66.44 Bn | -363.26 | 145.55 | 2.71 Bn |
| 5 | ALNY | Alnylam Pharmaceuticals, Inc. | 49.96 Bn | 1,146.87 | 15.56 | 3.21 Bn |
| 6 | ARGX | Argenx Se | 48.74 Bn | 32.36 | 25,415.62 | - |
| 7 | BNTC | Benitec Biopharma Inc. | 40.53 Bn | -969.17 | 0.00 | 0.00 Bn |
| 8 | INSM | INSMED Inc | 31.37 Bn | -26.50 | 70.18 | 0.74 Bn |
| Current Valuation | Value | Ind Avg | Percentile |
|---|---|---|---|
| EV to Assets EV to Assets | 1.20 | 11.64 | |
| EV to Cash from Ops. EV/CFO | -2.71 | 22.98 | |
| EV to Debt EV to Debt | 4.12 | 714.06 | |
| EV to EBIT EV/EBIT | -2.70 | -12.88 | |
| EV to EBITDA EV/EBITDA | -2.27 | 6.99 | |
| EV to Free Cash Flow [EV/FCF] EV/FCF | -2.70 | 21.89 | |
| EV to Market Cap EV to Market Cap | 0.86 | 103.76 | |
| EV to Revenue EV/Rev | 8.82 | 196.10 | |
| Price to Book Value [P/B] P/B | 25.04 | 21.83 | |
| Price to Earnings [P/E] P/E | -2.80 | -13.53 |
| Dividend Metrics | Value | Ind Avg | Percentile |
|---|---|---|---|
| Dividend Coverage Ratio Dividend Coverage Ratio | 0.00 | -12.07 | |
| Dividend Payout Ratio % Dividend Payout Ratio % | 0.00 | 0.17 | |
| Dividend per Basic Share Div per Share (Qtr) | 0.00 | 0.01 | |
| FCF Dividend Payout Ratio % FCF Dividend Payout Ratio % | 0.00 | -0.15 | |
| Interest Coverage Interest Coverage | -8.77 | 859.48 |
| Growth Metrics | Value | Ind Avg | Percentile |
|---|---|---|---|
| Capex Growth (1y) % Capex Growth (1y) % | -3.78 | -27.11 | |
| Cash and Equivalents Growth (1y) % Cash & Equiv 1y % (Qtr) | -16.05 | 749.91 | |
| Dividend Growth (1y) % Dividend Growth (1y) % | 0.00 | 0.01 | |
| EBIAT Growth (1y) % EBIAT Growth (1y) % | -45.34 | -51.60 | |
| EBITDA Growth (1y) % EBITDA Growth (1y) % | -49.34 | -4.49 | |
| EBIT Growth (1y) % EBIT Growth (1y) % | -45.34 | -61.23 | |
| EBT Growth (1y) % EBT Growth (1y) % | -47.97 | -18.17 | |
| EPS Growth (1y) % EPS Growth (1y) % | -43.28 | -3.33 | |
| FCF Growth (1y) % FCF Growth (1y) % | -147.60 | -32.98 | |
| Gross Profit Growth (1y) % Gross Profit Growth (1y) % | -59.08 | 228.66 |
| Liquidity Ratios | Value | Ind Avg | Percentile |
|---|---|---|---|
| Asset Utilization Ratio Asset Utilization Ratio | 0.16 | 0.14 | |
| Cash Payout Ratio Cash Payout Ratio | 0.00 | 0.00 | |
| Cash Ratio Cash Ratio (Qtr) | 1.83 | 3.79 | |
| Current Ratio Curr Ratio (Qtr) | 2.21 | 7.24 | |
| Debt to Equity Ratio Debt/Equity (Qtr) | 5.25 | 0.42 | |
| Interest Cover Ratio Interest Cover Ratio | -8.77 | 859.48 | |
| Times Interest Earned Times Interest Earned | -8.77 | 859.48 |
| Profitability | Value | Ind Avg | Percentile |
|---|---|---|---|
| EBITDA Margin % EBITDA Margin % | -314.80 | -17,651.95 | |
| EBIT Margin % EBIT Margin % | -278.07 | -18,005.40 | |
| EBT Margin % EBT Margin % | -364.44 | -18,859.43 | |
| Gross Margin % Gross Margin % | 100.00 | -8.65 | |
| Net Profit Margin % Net Profit Margin % | -364.40 | -18,808.76 |